

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 CA/CAPLUS records now contain indexing from 1907 to the
present
NEWS 4 AUG 05 New pricing for EUROPATFULL and PCTFULL effective
August 1, 2003
NEWS 5 AUG 13 Field Availability (/FA) field enhanced in BEILSTEIN
NEWS 6 AUG 18 Data available for download as a PDF in RDISCLOSURE
NEWS 7 AUG 18 Simultaneous left and right truncation added to PASCAL
NEWS 8 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Right
Truncation
NEWS 9 AUG 18 Simultaneous left and right truncation added to ANABSTR
NEWS 10 SEP 22 DIPPR file reloaded
NEWS 11 SEP 25 INPADOC: Legal Status data to be reloaded
NEWS 12 SEP 29 DISSABS now available on STN
NEWS 13 OCT 10 PCTFULL: Two new display fields added
NEWS 14 OCT 21 BIOSIS file reloaded and enhanced
NEWS 15 OCT 28 BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 16 NOV 24 MSDS-CCOHS file reloaded

NEWS EXPRESS NOVEMBER 14 CURRENT WINDOWS VERSION IS V6.01c, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:16:39 ON 05 DEC 2003

=> file medline, uspatful, dgene, embase, wpids, fsta, jicst, biosis
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'MEDLINE' ENTERED AT 08:17:09 ON 05 DEC 2003

FILE 'USPATFULL' ENTERED AT 08:17:09 ON 05 DEC 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 08:17:09 ON 05 DEC 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 08:17:09 ON 05 DEC 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 08:17:09 ON 05 DEC 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 08:17:09 ON 05 DEC 2003
COPYRIGHT (C) 2003 International Food Information Service

FILE 'JICST-EPLUS' ENTERED AT 08:17:09 ON 05 DEC 2003
COPYRIGHT (C) 2003 Japan Science and Technology Agency (JST)

FILE 'BIOSIS' ENTERED AT 08:17:09 ON 05 DEC 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

=> s atopic dermatitis
L1 62880 ATOPIC DERMATITIS

=> s MC148P
L2 6 MC148P

=> d l2 ti abs ibib tot

L2 ANSWER 1 OF 6 USPATFULL on STN
TI Atopic dermatitis treatment method
AB Compositions are provided for treating atopic dermatitis, other atopic diseases and other inflammatory or allergic skin disorders. The compositions include proteins from Molluscum Contagiosum Virus (MCV), or fragments, variants, analogs, and derivatives thereof which exhibit AD inhibiting activity. Examples of MCV proteins which exhibit AD inhibiting activity include MC148P1, MC148P2, MC148P3, other **MC148P** type proteins, and fragments, variants, analogs, and derivatives of MC148P1, MC148P2, MC148P3, and other **MC148P** type-proteins which possess AD inhibiting activity. The fragments, variants, analogs and derivatives may be less than 100 % homologous to MCV proteings so long as they are sufficiently homologous such that AD inhibiting activity is preserved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:16613 USPATFULL
TITLE: Atopic dermatitis treatment method
INVENTOR(S): Paslin, David A., San Mateo, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002009489	A1	20020124
APPLICATION INFO.:	US 2001-920897	A1	20010801 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-624748, filed on 24 Jul 2000, PENDING Continuation of Ser. No. US 1999-426093, filed on 22 Oct 1999, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 943041050		
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Page(s)		

LINE COUNT: 721
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 2 OF 6 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI Treating atopic dermatitis, inflammations and allergic skin disorders by
administering **MC148P** proteins from Molluscum Contagiosum Virus

AN AAU76904 Protein DGENE

AB This invention relates to a novel method for treating atopic dermatitis,
other atopic diseases and other inflammatory and/or allergic skin
disorders. The method comprises administering a molluscum contagiosum
Virus **MC148P** protein (specifically MC148P1, MC148P2, MC148P3)
MC148P. The method of the invention may have dermatological,
anti-allergic, anti-inflammatory and anti-asthmatic activities. The
MC148P protein is administered to treat atopic dermatitis, other
atopic diseases and other inflammatory and/or allergic skin disorders.
The present sequence represents the molluscum contagiosum virus MC148
type 2 protein used in the method of the invention.

ACCESSION NUMBER: AAU76904 Protein DGENE

TITLE: Treating atopic dermatitis, inflammations and allergic skin
disorders by administering **MC148P** proteins from
Molluscum Contagiosum Virus -

INVENTOR: Paslin D A

PATENT ASSIGNEE: (PASL-I) PASLIN D A.

PATENT INFO: US 2002009489 A1 20020124

16p

APPLICATION INFO: US 2001-920897 20010801

PRIORITY INFO: US 1999-426093 19991022

US 2000-624748 20000724

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2002-138958 [18]

CROSS REFERENCES: N-PSDB: ABK10280

DESCRIPTION: Molluscum contagiosum virus MCV148 type 2 protein.

L2 ANSWER 3 OF 6 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI Treating atopic dermatitis, inflammations and allergic skin disorders by
administering **MC148P** proteins from Molluscum Contagiosum Virus

AN AAU76903 Protein DGENE

AB This invention relates to a novel method for treating atopic dermatitis,
other atopic diseases and other inflammatory and/or allergic skin
disorders. The method comprises administering a molluscum contagiosum
Virus **MC148P** protein (specifically MC148P1, MC148P2, MC148P3)
MC148P. The method of the invention may have dermatological,
anti-allergic, anti-inflammatory and anti-asthmatic activities. The
MC148P protein is administered to treat atopic dermatitis, other
atopic diseases and other inflammatory and/or allergic skin disorders.
The present sequence represents the molluscum contagiosum virus MC148
type I protein used in the method of the invention.

ACCESSION NUMBER: AAU76903 Protein DGENE

TITLE: Treating atopic dermatitis, inflammations and allergic skin
disorders by administering **MC148P** proteins from
Molluscum Contagiosum Virus -

INVENTOR: Paslin D A

PATENT ASSIGNEE: (PASL-I) PASLIN D A.

PATENT INFO: US 2002009489 A1 20020124

16p

APPLICATION INFO: US 2001-920897 20010801

PRIORITY INFO: US 1999-426093 19991022

US 2000-624748 20000724

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2002-138958 [18]

CROSS REFERENCES: N-PSDB: ABK10279

DESCRIPTION: Molluscum contagiosum virus MCV148 type I protein.

L2 ANSWER 4 OF 6 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
 TI Treating atopic dermatitis, inflammations and allergic skin disorders by administering **MC148P** proteins from Molluscum Contagiosum Virus
 -
 AN ABK10280 DNA DGENE
 AB This invention relates to a novel method for treating atopic dermatitis, other atopic diseases and other inflammatory and/or allergic skin disorders. The method comprises administering a molluscum contagiosum Virus **MC148P** protein (specifically MC148P1, MC148P2, MC148P3) **MC148P**. The method of the invention may have dermatological, anti-allergic, anti-inflammatory and anti-asthmatic activities. The **MC148P** protein is administered to treat atopic dermatitis, other atopic diseases and other inflammatory and/or allergic skin disorders. The present sequence represents the cDNA encoding the molluscum contagiosum virus MC148 type 2 protein used in the method of the invention. This sequence corresponds to nucleotides 166,992 - 167,303 of the MCV genome.

ACCESSION NUMBER: ABK10280 DNA DGENE
 TITLE: Treating atopic dermatitis, inflammations and allergic skin disorders by administering **MC148P** proteins from Molluscum Contagiosum Virus -
 INVENTOR: Paslin D A
 PATENT ASSIGNEE: (PASL-I)PASLIN D A.
 PATENT INFO: US 2002009489 A1 20020124 16p
 APPLICATION INFO: US 2001-920897 20010801
 PRIORITY INFO: US 1999-426093 19991022
 US 2000-624748 20000724
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 OTHER SOURCE: 2002-138958 [18]
 CROSS REFERENCES: P-PSDB: AAU76904
 DESCRIPTION: cDNA encoding molluscum contagiosum virus MCV148 type 2 protein.

L2 ANSWER 5 OF 6 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
 TI Treating atopic dermatitis, inflammations and allergic skin disorders by administering **MC148P** proteins from Molluscum Contagiosum Virus
 -
 AN ABK10279 DNA DGENE
 AB This invention relates to a novel method for treating atopic dermatitis, other atopic diseases and other inflammatory and/or allergic skin disorders. The method comprises administering a molluscum contagiosum Virus **MC148P** protein (specifically MC148P1, MC148P2, MC148P3) **MC148P**. The method of the invention may have dermatological, anti-allergic, anti-inflammatory and anti-asthmatic activities. The **MC148P** protein is administered to treat atopic dermatitis, other atopic diseases and other inflammatory and/or allergic skin disorders. The present sequence represents the cDNA encoding the molluscum contagiosum virus MC148 type I protein used in the method of the invention. This sequence corresponds to nucleotides 166,992-167,303 of the MCV genome.

ACCESSION NUMBER: ABK10279 DNA DGENE
 TITLE: Treating atopic dermatitis, inflammations and allergic skin disorders by administering **MC148P** proteins from Molluscum Contagiosum Virus -
 INVENTOR: Paslin D A
 PATENT ASSIGNEE: (PASL-I)PASLIN D A.
 PATENT INFO: US 2002009489 A1 20020124 16p
 APPLICATION INFO: US 2001-920897 20010801
 PRIORITY INFO: US 1999-426093 19991022
 US 2000-624748 20000724
 DOCUMENT TYPE: Patent
 LANGUAGE: English

OTHER SOURCE: 2002-138958 [18]
CROSS REFERENCES: P-PSDB: AAU76903
DESCRIPTION: cDNA encoding molluscum contagiosum virus MCV148 type I protein.

L2 ANSWER 6 OF 6 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
TI Treating atopic dermatitis, inflammations and allergic skin disorders by administering **MC148P** proteins from Molluscum Contagiosum Virus.
AN 2002-138958 [18] WPIDS
AB US2002009489 A UPAB: 20020319
NOVELTY - A method and kit for treating atopic dermatitis, other atopic diseases and other inflammatory and/or allergic skin disorders, by administering an **MC148P** protein (specifically MC148P1, MC148P2, MC148P3), are new. **MC148P** Proteins are derived from Molluscum Contagiosum Virus.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

(1) a method (I), comprising administering, to a patient having atopic dermatitis, a composition comprising a **MC148P** protein which possesses atopic dermatitis inhibiting activity; and
(2) a kit (II), comprising multiple separately packaged portions of a composition adapted for treating atopic dermatitis comprising a **MC148P** protein which possesses atopic dermatitis inhibiting activity.

ACTIVITY - Dermatological; anti-allergic; anti-inflammatory; anti-asthmatic.

No quantitative biological data given.

MECHANISM OF ACTION - None given.

USE - The **MC148P** protein is administered to treat atopic dermatitis, other atopic diseases and other inflammatory and/or allergic skin disorders (claimed).

Dwg.0/5

ACCESSION NUMBER: 2002-138958 [18] WPIDS
DOC. NO. CPI: C2002-042742
TITLE: Treating atopic dermatitis, inflammations and allergic skin disorders by administering **MC148P** proteins from Molluscum Contagiosum Virus.
DERWENT CLASS: B04 D16
INVENTOR(S): PASLIN, D A
PATENT ASSIGNEE(S): (PASL-I) PASLIN D A
COUNTRY COUNT: 1
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2002009489	A1	20020124	(200218)*		15

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2002009489	A1	Cont of	US 1999-426093 19991022
		Cont of	US 2000-624748 20000724
			US 2001-920897 20010801

PRIORITY APPLN. INFO: US 1999-426093 19991022; US 2000-624748 20000724; US 2001-920897 20010801

=> d his

(FILE 'HOME' ENTERED AT 08:16:39 ON 05 DEC 2003)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS,
BIOSIS' ENTERED AT 08:17:09 ON 05 DEC 2003

L1 62880 S ATOPIC DERMATITIS
L2 6 S MC148P

=> s l1 and treatment
L3 17364 L1 AND TREATMENT

=> s molluscum contagiosum virus or MCV
L4 7261 MOLLUSCUM CONTAGIOSUM VIRUS OR MCV

=> s l4 and l3
L5 18 L4 AND L3

=> d l5 ti abs ibib tot

L5 ANSWER 1 OF 18 MEDLINE on STN

TI [Atopic dermatitis and pox-virus superinfections
(author's transl)].

Dermatite atopique et surinfection a pox-virus.

AB Subjects afflicted with **atopic dermatitis** are particularly predisposed to such viral superinfections as verruca, herpes (eczema herpeticum) and vaccinia (eczema vaccinatum). Knowledge of superinfection by the **molluscum contagiosum virus** is more recent and the authors describe one case. The orf virus (responsible for ovine ecthyma contagiosum), however, has never been described as responsible for the profuse superinfection of an atopic eczema. The authors observed one case of this in a child, atypical as result of his age (16 months), the cervical localization and the aspect, which was a telangiectasic granuloma type of the initial element, and finally of the satellization observed one week later. This child suffered from a generalized atopic eczema. Propagation of the orf lesions could have been favored by scratching, local corticoid **treatment** and by the deficit in cellular immunity observed in patient with **atopic dermatitis**. Indeed, viral superinfections, which are unusual by their profusion or their chronic nature, are often observed in immunodepressed subjects.

ACCESSION NUMBER: 82111890 MEDLINE

DOCUMENT NUMBER: 82111890 PubMed ID: 6275765

TITLE: [Atopic dermatitis and pox-virus
superinfections (author's transl)].
Dermatite atopique et surinfection a pox-virus.

AUTHOR: Dupre A; Christol B; Lassere J

SOURCE: ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, (1981) 108 (11)
829-34.

Journal code: 7702013. ISSN: 0151-9638.

PUB. COUNTRY: France

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: French

FILE SEGMENT: Priority Journals

ENTRY MONTH: 198203

ENTRY DATE: Entered STN: 19900317

Last Updated on STN: 19900317

Entered Medline: 19820313

L5 ANSWER 2 OF 18 USPATFULL on STN

TI Preventive or therapeutic agent for pollen allergy, allergic rhinitis,
atopic dermatitis, asthma or urticaria, or health food
for prevention or improvement or reduction of symptoms thereof

AB A method for prevention or therapy of pollen allergy, allergic rhinitis,
atopic dermatitis, asthma or urticaria by
administration of two kinds of crude drugs--seeds of Cucurbita moschata
and flowers of Carthamus tinctorius--and at least one crude drug
selected from Plantago asiatica, Lonicera japonica, Glycyrrhiza

uralensis, Coix lachrymal-jobi var, ma-yuen, Zingiber officinale, Curcuma longa, Curcuma zedoaria and Artemisia argyi to a patient; and a health food for prevention, or improvement, or reduction of these symptoms containing the above substances.

ACCESSION NUMBER: 2003:282356 USPATFULL
TITLE: Preventive or therapeutic agent for pollen allergy,
allergic rhinitis, **atopic dermatitis**
, asthma or urticaria, or health food for prevention or
improvement or reduction of symptoms thereof
INVENTOR(S): Yoshida, Satoshi, Tokyo, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003198697	A1	20031023
APPLICATION INFO.:	US 2002-126779	A1	20020422 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow,, Garrett & Dunner, L.L.P., 1300 I Street, N.W., Washington, DC, 20005-3315		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Page(s)		
LINE COUNT:	800		

L5 ANSWER 3 OF 18 USPATFULL on STN
TI Compounds and methods for modulating CXCR3 function
AB Compounds and compositions are provided that bind to the CXCR3 chemokine
receptor and which are useful for treating diseases associated with
CXCR3 activity, such as multiple sclerosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:174006 USPATFULL
TITLE: Compounds and methods for modulating CXCR3 function
INVENTOR(S): Schall, Thomas J., Palo Alto, CA, UNITED STATES
Dairaghi, Daniel J., Palo Alto, CA, UNITED STATES
McMaster, Brian E., Mountain View, CA, UNITED STATES
PATENT ASSIGNEE(S): ChemoCentryx, Inc., San Carlos, CA, UNITED STATES,
94070 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003119854	A1	20030626
APPLICATION INFO.:	US 2002-279353	A1	20021023 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-648329, filed on 25 Aug 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-151212P	19990827 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1608	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 18 USPATFULL on STN
TI Compounds and methods for modulating cxcr3 function
AB The invention provides compounds and compositions of the formula:
##STR1##

wherein

the subscript n is an integer of from 0 to 4;

Ar is a member selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;

R.sup.1 is a member selected from the group consisting of substituted or unsubstituted (C.sub.5-C.sub.15)alkyl;

R.sup.2 is a member selected from the group consisting of substituted or unsubstituted (C.sub.1-C.sub.8)alkyl;

each R.sup.3 is independently a substituent selected from -halogen, --OR', --OC(O)R', --NR'R", --SR', --R', --CN, --NO.sub.2, --CO.sub.2R', --CONR'R", --C(O)R', --OC(O)NR'R", --NR"C(O)R', --NR"C(O).sub.2R', , --NR'--C(O)NR'R", --NH--C(NH.sub.2).dbd.NH, --NR'C(NH.sub.2).dbd.NH, --NH--C(NH.sub.2).dbd.NR--, --S(O)R', --S(O).sub.2R', --S(O).sub.2NR'R", --N.sub.3, --CH(Ph).sub.2, perfluoro(C.sub.1-C.sub.4)alkoxy, and perfluoro(C.sub.1-C.sub.4)alkyl, and where R', R" and R'" are independently selected from hydrogen, (C.sub.1-C.sub.8)alkyl and heteroalkyl, unsubstituted aryl and heteroaryl, (unsubstituted aryl)-(C.sub.1-C.sub.4)alkyl, and (unsubstituted aryl)oxy-(C.sub.1-C.sub.4)alkyl;

Y is a member selected from the group consisting of substituted or unsubstituted (C.sub.2-C.sub.8)alkylene and substituted or unsubstituted (C.sub.2-C.sub.8)heteroalkylene;

and Z is --NR.sup.4R.sup.5, wherein R.sup.4 and R.sup.5 are independently selected from the group consisting of hydrogen and (C.sub.1-C.sub.8)alkyl.

These compounds and compositions bind to the CXCR3 chemokine receptor and are useful for treating diseases and conditions responsive to the modulation of CXCR3 activity, such as multiple sclerosis, rheumatoid arthritis, psoriasis, cancer, infectious disease, angiogenesis, and graft rejection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:123349 USPATFULL
TITLE: Compounds and methods for modulating cxcr3 function
INVENTOR(S): Schall, Thomas J., Palo Alto, CA, United States
Dairaghi, Daniel J., Palo Alto, CA, United States
McMaster, Brian E., Mountain View, CA, United States
PATENT ASSIGNEE(S): Chemocentryx, Inc., San Carlos, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6559160	B1	20030506
APPLICATION INFO.:	US 2000-648329		20000825 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-151212P	19990827 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Shah, Mukund J.	
ASSISTANT EXAMINER:	Habte, Kahsay	
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew LLP	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	

LINE COUNT: 1781
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 18 USPATFULL on STN

TI Blood cell deficiency **treatment** method

AB The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3.beta.-yl)-.beta.-D-glucopyranosiduronate, 16.alpha.,3.alpha.-dihydroxy-5.alpha.-androstane-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the **treatment** method.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:120747 USPATFULL

TITLE: Blood cell deficiency **treatment** method

INVENTOR(S): Ahlem, Clarence N., San Diego, CA, UNITED STATES
Reading, Christopher, San Diego, CA, UNITED STATES
Frincke, James, San Diego, CA, UNITED STATES
Stickney, Dwight, Granite Bay, CA, UNITED STATES
Lardy, Henry A., Madison, WI, UNITED STATES
Marwah, Padma, Middleton, WI, UNITED STATES
Marwah, Ashok, Middleton, WI, UNITED STATES
Prendergast, Patrick T., Straffan, IRELAND

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003083231	A1	20030501
APPLICATION INFO.:	US 2002-87929	A1	20020301 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-675470, filed on 28 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2001-820483, filed on 29 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-535675, filed on 23 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1999-449004, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449184, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449042, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-461026, filed on 15 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-586673, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-586672, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-414905, filed on 8 Oct 1999, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-161453P	19991025 (60)
	US 2001-272624P	20010301 (60)
	US 2001-323016P	20010911 (60)
	US 2001-340045P	20011130 (60)
	US 2001-328738P	20011011 (60)
	US 2001-338015P	20011108 (60)
	US 2001-343523P	20011220 (60)
	US 1999-126056P	19991019 (60)
	US 1999-124087P	19990311 (60)
	US 1998-109923P	19981124 (60)
	US 1998-109924P	19981124 (60)
	US 1998-110127P	19981127 (60)
	US 1998-112206P	19981215 (60)
	US 1999-145823P	19990727 (60)
	US 1999-137745P	19990603 (60)

US 1999-140028P 19990616 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL,
SUITE 400, SAN DIEGO, CA, 92121
NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1
LINE COUNT: 19428
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 18 USPATFULL on STN
TI CXCR3 antagonists
AB Compounds, compositions and methods that are useful in the
treatment of inflammatory and immune conditions and diseases are
provided herein. In particular, the invention provides compounds which
modulate the expression and/or function of a chemokine receptor. The
subject methods are useful for the **treatment** of inflammatory
and immunoregulatory disorders and diseases, such as multiple sclerosis,
rheumatoid arthritis and type I diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:100123 USPATFULL
TITLE: CXCR3 antagonists
INVENTOR(S): Medina, Julio C., San Carlos, CA, UNITED STATES
Johnson, Michael G., San Francisco, CA, UNITED STATES
Li, An-Rong, So. San Francisco, CA, UNITED STATES
Liu, Jiwen, Belmont, CA, UNITED STATES
Huang, Alan Xi, San Mateo, CA, UNITED STATES
Zhu, Liusheng, Burlingame, CA, UNITED STATES
Marcus, Andrew P., San Francisco, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003069234	A1	20030410
APPLICATION INFO.:	US 2002-164690	A1	20020606 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-296499P	20010606 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Pennie & Edmonds, LLP, 3300 Hillview Avenue, Palo Alto, CA, 94304	
NUMBER OF CLAIMS:	135	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Page(s)	
LINE COUNT:	5271	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 18 USPATFULL on STN
TI CXCR3 antagonists
AB Compounds, compositions and methods that are useful in the
treatment of inflammatory and immune conditions and diseases are
provided herein. In particular, the invention provides compounds which
modulate the expression and/or function of a chemokine receptor. The
subject methods are useful for the **treatment** of inflammatory
and immunoregulatory disorders and diseases, such as multiple sclerosis,
rheumatoid arthritis and type I diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:79127 USPATFULL
TITLE: CXCR3 antagonists
INVENTOR(S): Medina, Julio C., San Carlos, CA, UNITED STATES
Johnson, Michael G., San Francisco, CA, UNITED STATES

Li, An-Rong, So. San Francisco, CA, UNITED STATES
Liu, Jiwen, Belmont, CA, UNITED STATES
Huang, Alan Xi, San Mateo, CA, UNITED STATES
Zhu, Liusheng, Burlingame, CA, UNITED STATES
Marcus, Andrew P., San Francisco, CA, UNITED STATES
Tularik, Inc. (U.S. corporation)

PATENT ASSIGNEE(S):

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003055054	A1	20030320
APPLICATION INFO.:	US 2002-231895	A1	20020829 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-15532, filed on 11 Dec 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-255241P	20001211 (60)
	US 2001-296499P	20010606 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711	
NUMBER OF CLAIMS:	135	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Page(s)	
LINE COUNT:	5270	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L5 ANSWER 8 OF 18 USPATFULL on STN

TI Apoptosis related polynucleotides, polypeptides, and antibodies
AB The present invention relates to novel human apoptosis related polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human apoptosis related polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human apoptosis related polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:71447 USPATFULL
TITLE: Apoptosis related polynucleotides, polypeptides, and antibodies
INVENTOR(S): Ni, Jian, Germantown, MD, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003049732	A1	20030313
APPLICATION INFO.:	US 2001-13477	A1	20011213 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-669445, filed on 25 Sep 2000, PENDING Continuation-in-part of Ser. No. WO 2000-US6642, filed on 15 Mar 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-126018P	19990324 (60)
	US 1999-139638P	19990617 (60)
	US 1999-149449P	19990818 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,	

ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
LINE COUNT: 12594
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 18 USPATFULL on STN
TI Agent for the anti-adhesion of skin pathogenic flora
AB Bacterial agents for preparing compositions which are for cosmetic, pharmaceutical or veterinary use and which are intended to stabilize and/or regulate the cutaneous ecosystem of mammals. These bacterial agents are extracts of a bacterium, or a bacterium and are selected for their adhesion to skin cells and anti-adhesion to pathogens of the cutaneous system. The invention also relates to compositions containing such agents.

ACCESSION NUMBER: 2003:70946 USPATFULL
TITLE: Agent for the anti-adhesion of skin pathogenic flora
INVENTOR(S): Baur, Markus, Stuttgart, GERMANY, FEDERAL REPUBLIC OF
Zink, Ralf, Le Mont Pelerin, SWITZERLAND
Auzanneau, Isabelle, Opio, FRANCE
Buffard, Karine, Sevres, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003049231	A1	20030313
APPLICATION INFO.:	US 2002-177589	A1	20020621 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2000-EP12719, filed on 13 Dec 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1999-204489	19991222
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WINSTON & STRAWN, PATENT DEPARTMENT, 1400 L STREET, N.W., WASHINGTON, DC, 20005-3502	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	833	

L5 ANSWER 10 OF 18 USPATFULL on STN
TI Ccr4 antagonists
AB Compounds, compositions and methods are provided that are useful in the **treatment** of chemokine receptor-mediated conditions and diseases. In particular, the invention provides compounds which modulate CCR4 function or a CCR4-mediated response. The subject compounds and compositions are useful for the **treatment** or prevention of inflammatory conditions and diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:24179 USPATFULL
TITLE: Ccr4 antagonists
INVENTOR(S): Collins, Tassie, San Mateo, CA, UNITED STATES
Mahmud, Hossen, San Antonio, TX, UNITED STATES
Houze, Jonathan, San Mateo, CA, UNITED STATES
Huang, Alan Xi, San Mateo, CA, UNITED STATES
Medina, Julio C., San Carlos, CA, UNITED STATES
Wang, Xuemei, San Mateo, CA, UNITED STATES
Xu, Feng, Palo Alto, CA, UNITED STATES
Xu, Qingge, Burlingame, CA, UNITED STATES
Zhu, Liusheng, Burlingame, CA, UNITED STATES
PATENT ASSIGNEE(S): Tularik Inc., So. San Francisco, CA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003018022	A1	20030123
APPLICATION INFO.:	US 2002-155605	A1	20020522 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-293781P	20010523 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Tularik Inc., Two Corporate Drive, So. San Francisco, CA, 94080	
NUMBER OF CLAIMS:	69	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	2212	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 11 OF 18 USPATFULL on STN
 TI Modulation of CCR4 function
 AB Compounds and compositions are provided that bind to the CCR4 chemokine receptor and which are useful for treating diseases associated with CCR4 activity, such as contact hypersensitivity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:308398 USPATFULL
 TITLE: Modulation of CCR4 function
 INVENTOR(S): Collins, Tassie, San Mateo, CA, UNITED STATES
 Dairaghi, Daniel J., Palo Alto, CA, UNITED STATES
 Mahmud, Hossen, San Antonio, TX, UNITED STATES
 McMaster, Brian E., Mountain View, CA, UNITED STATES
 Medina, Julio C., San Carlos, CA, UNITED STATES
 Schall, Thomas J., Palo Alto, CA, UNITED STATES
 Xu, Feng, Palo Alto, CA, UNITED STATES
 Wang, Xuemei, San Mateo, CA, UNITED STATES
 PATENT ASSIGNEE(S): Tularik Inc., So. San Francisco, CA, UNITED STATES, 94080 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002173524	A1	20021121
APPLICATION INFO.:	US 2001-975566	A1	20011011 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-240022P	20001011 (60)
	US 2001-293781P	20010523 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834	
NUMBER OF CLAIMS:	84	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	2267	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 12 OF 18 USPATFULL on STN
 TI CXCR3 antagonists
 AB Compounds, compositions and methods that are useful in the **treatment** of inflammatory and immune conditions and diseases are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of a chemokine receptor. The subject methods are useful for the **treatment** of inflammatory

and immunoregulatory disorders and diseases, such as multiple sclerosis, rheumatoid arthritis and type I diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:301614 USPATFULL
TITLE: CXCR3 antagonists
INVENTOR(S): Medina, Julio C., San Carlos, CA, UNITED STATES
Johnson, Michael G., San Francisco, CA, UNITED STATES
Li, An-Rong, So. San Francisco, CA, UNITED STATES
Liu, Jiwen, Belmont, CA, UNITED STATES
Xi Huang, Alan, San Mateo, CA, UNITED STATES
Zhu, Liusheng, Burlingame, CA, UNITED STATES
Marcus, Andrew P., San Francisco, CA, UNITED STATES
PATENT ASSIGNEE(S): Tularik Inc., San Francisco, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002169159	A1	20021114
APPLICATION INFO.:	US 2001-15532	A1	20011211 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-255241P	20001211 (60)
	US 2001-296499P	20010606 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711	
NUMBER OF CLAIMS:	135	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Page(s)	
LINE COUNT:	5284	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 13 OF 18 USPATFULL on STN

TI Method of inhibiting stenosis and restenosis

AB The invention relates to a method of inhibiting stenosis or restenosis in a subject. In one embodiment, an agent which inhibits recruitment and/or adhesion of neutrophils and mononuclear cells to a site of vascular injury is administered to a subject in need thereof. In another embodiment, a first agent which inhibits recruitment and/or adhesion of neutrophils to a site of vascular injury, and a second agent which inhibits recruitment and/or adhesion of mononuclear cells to a site of vascular injury are administered to a subject in need thereof. In particular embodiments, the agents are antibodies or antigen-binding fragments thereof which bind to CD 18 or CCR2.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:198275 USPATFULL
TITLE: Method of inhibiting stenosis and restenosis
INVENTOR(S): Horvath, Christopher J., Taunton, MA, UNITED STATES
Rao, Patricia E., Acton, MA, UNITED STATES
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002106369	A1	20020808
APPLICATION INFO.:	US 2001-809739	A1	20010315 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-528267, filed on 17 Mar 2000, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		

LEGAL REPRESENTATIVE: HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA
ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 36 Drawing Page(s)
LINE COUNT: 2234
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 14 OF 18 USPATFULL on STN

TI **Atopic dermatitis treatment** method

AB Compositions are provided for treating **atopic dermatitis**, other atopic diseases and other inflammatory or allergic skin disorders. The compositions include proteins from **Molluscum Contagiosum Virus (MCV)**, or fragments, variants, analogs, and derivatives thereof which exhibit AD inhibiting activity. Examples of **MCV** proteins which exhibit AD inhibiting activity include MC148P1, MC148P2, MC148P3, other MC148P type proteins, and fragments, variants, analogs, and derivatives of MC148P1, MC148P2, MC148P3, and other MC148P type-proteins which possess AD inhibiting activity. The fragments, variants, analogs and derivatives may be less than 100 % homologous to **MCV** proteings so long as they are sufficiently homologous such that AD inhibiting activity is preserved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:16613 USPATFULL

TITLE: **Atopic dermatitis treatment**
method

INVENTOR(S): Paslin, David A., San Mateo, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002009489	A1	20020124
APPLICATION INFO.:	US 2001-920897	A1	20010801 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-624748, filed on 24 Jul 2000, PENDING Continuation of Ser. No. US 1999-426093, filed on 22 Oct 1999, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 943041050		
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Page(s)		
LINE COUNT:	721		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 15 OF 18 USPATFULL on STN

TI Therapeutic agent and method for feline AIDS virus infections and feline **atopic dermatitis**

AB A therapeutic agent for feline immunodeficiency virus (FIV) infections, (including the **treatment** of the anemia and chronic stomatitis caused by infection with a FIV) comprising a feline interferon preparation containing a feline interferon as a principal agent, and a therapeutic method for FIV infections comprising administering a feline interferon preparation containing a feline interferon as a principal agent to a cat every day are disclosed. Furthermore, a therapeutic method and agent for feline **atopic dermatitis** are disclosed. The preferred feline interferon, is an .omega.-feline interferon.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:29533 USPATFULL

TITLE: Therapeutic agent and method for feline AIDS virus

infections and feline **atopic
dermatitis**

INVENTOR(S): Kajimoto, Tsunesuke, Kanagawa, Japan
Go, Ryougai, Houston, TX, United States
Suzuki, Makoto, Aichi, Japan
PATENT ASSIGNEE(S): Toray Industries, Inc., Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6194381	B1	20010227
	WO 9818484		19980507
APPLICATION INFO.:	US 1998-101144		19981119 (9)
	WO 1997-JP3963		19971030
			19981119 PCT 371 date
			19981119 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1996-290601	19961031
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Low, Christopher S. F.	
ASSISTANT EXAMINER:	Gupta, Anish	
LEGAL REPRESENTATIVE:	Miller, Austin R.	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
LINE COUNT:	476	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 16 OF 18 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

TI Azathioprine in dermatological practice: An overview with special emphasis
on its use in non-bullous inflammatory dermatoses.

AB Azathioprine is employed for its immunosuppressive properties, as a
steroid-sparing agent or as monotherapy. Its most traditional clinical
indications are connective tissue diseases, vasculitis, post-transplant,
and immunobullous dermatoses. The main disadvantages of azathioprine
therapy are a delayed onset of action (6-8 weeks), and rare profound bone
marrow toxicity. Susceptibility to bone marrow toxicity is due to a
genetically determined metabolic defect (1 in 300). Patients at risk of
such toxicity may be identified by a Thiopurine methyltransferase enzyme
assay. We have undertaken a retrospective study, looking at the use of
azathioprine as monotherapy for non-bullous inflammatory, dermatoses. We
studied a total of 24 patients (10 male, 14 female). The dermatoses
comprised: atopic eczema (10), pompholyx (6), plaque psoriasis (6), and
chronic actinic dermatitis (2). All patients had severe refractory disease
warranting systemic second line therapy. The mean age was 49.4 years
(range 17-86 years). The starting dose of azathioprine was 100-150 mg/day,
and the maintenance dose 50-100 mg/day. The mean duration of
treatment was 33.5 months (range 1-132 months). Eighteen patients
(75%) showed a good to excellent sustained clinical response to
azathioprine. This response rate was evenly represented in the 4
dermatoses studied. The adverse reactions encountered were raised
MCV (6), leucopenia (2), raised hepatic enzymes (6), and dyspepsia
(4). Azathioprine had to be discontinued due to adverse reactions in 2
patients (dyspepsia, raised hepatic enzymes) followed by normalisation.
Other factors that potentially contributed to the observed adverse events
were present in 5 patients: alcoholism (2), erythromycin toxicity (1), and
malabsorption (2). Our study demonstrates the efficacy of azathioprine
monotherapy for severe atopic eczema, pompholyx, plaque psoriasis, and
chronic actinic dermatitis. Furthermore, azathioprine is a low cost and
generally well tolerated drug.

ACCESSION NUMBER: 2001088570 EMBASE

TITLE: Azathioprine in dermatological practice: An overview with

special emphasis on its use in non-bullous inflammatory dermatoses.

AUTHOR: Scerri L.
 CORPORATE SOURCE: L. Scerri, Sir Paul Boffa Hospital, Floriana, Malta
 SOURCE: Advances in Experimental Medicine and Biology, (1999) 455/- (343-348).
 Refs: 11
 ISSN: 0065-2598 CODEN: AEMBAP

COUNTRY: United States
 DOCUMENT TYPE: Journal; Conference Article
 FILE SEGMENT: 013 Dermatology and Venereology
 030 Pharmacology
 037 Drug Literature Index
 038 Adverse Reactions Titles

LANGUAGE: English
 SUMMARY LANGUAGE: English

L5 ANSWER 17 OF 18 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.
 on STN

TI [Atopic dermatitis and pox-virus superinfections].

DERMATITE ATOPIQUE ET SURINFECTION A POX-VIRUS.

AB Subjects afflicted with **atopic dermatitis** are particularly predisposed to such viral superinfections as verruca, herpes (eczema herpeticum) and vaccinia (eczema vaccinatum). Knowledge of superinfection by the **molluscum contagiosum virus** is more recent and the authors describe one case. The orf virus (responsible for ovine ecthyma contagiosum), however, has never been described as responsible for the profuse superinfection of an atopic eczema. The authors observed one case of this in a child which was considered atypical because of his age (16 months), the cervical localization and the aspect, which was a telangiectasic granuloma type of the initial element, and finally of the satellization observed one week later. This child suffered from a generalized atopic eczema. Propagation of the orf lesions could have been favored by scratching, local corticoid **treatment** and by the deficit in cellular immunity observed in patients with **atopic dermatitis**. Indeed, viral superinfections, which are unusual by their profusion or their chronic nature, are often observed in immunodepressed subjects.

ACCESSION NUMBER: 82058467 EMBASE

DOCUMENT NUMBER: 1982058467

TITLE: [Atopic dermatitis and pox-virus superinfections].
 DERMATITE ATOPIQUE ET SURINFECTION A POX-VIRUS.

AUTHOR: Dupre A.; Christol B.; Lassere J.

CORPORATE SOURCE: Serv. Dermatol., Hop. La Grave, F-31052 Toulouse, France

SOURCE: Annales de Dermatologie et de Venereologie, (1981) 108/11 (829-834).
 CODEN: ADVED7

COUNTRY: France

DOCUMENT TYPE: Journal

FILE SEGMENT: 013 Dermatology and Venereology
 047 Virology

LANGUAGE: French

SUMMARY LANGUAGE: English

L5 ANSWER 18 OF 18 JICST-EPlus COPYRIGHT 2003 JST on STN

TI Informed Consent in the **Treatment** of Pediatric Surgical Diseases. (II). Molluscum Contagiosum.

AB Molluscum contagiosum(MC) is an infectious benign skin disease caused by molluscum contagiosum virus(MCV), which is a member of the human poxviruses. In the last decade, the number of patients with MC has increased as more children attend swimming schools in Japan. However, the effective **treatment** for MC is still surgical removal with blunt forceps, which unfortunately gives great pain. Therefore, the

establishment of a new therapeutic modality is needed. (author abst.)
ACCESSION NUMBER: 930607451 JICST-EPlus
TITLE: Informed Consent in the **Treatment** of Pediatric
Surgical Diseases. (II). Molluscum Contagiosum.
AUTHOR: YAMASHITA HIROKO; KAWASHIMA MAKOTO
CORPORATE SOURCE: Tokyo Women's Medical College
SOURCE: Shoni Geka (Japanese Journal of Pediatric Surgery), (1993)
vol. 25, no. 6, pp. 649-652. Journal Code: Z0323B (Fig. 3,
Tbl. 1, Ref. 11)
ISSN: 0385-6313
PUB. COUNTRY: Japan
DOCUMENT TYPE: Journal; Commentary
LANGUAGE: Japanese
STATUS: New

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Terms	Documents
L7 and inotophoresis	2

Database:

[US Patents Full-Text Database](#)
[US Pre-Grant Publication Full-Text Database](#)
[JPO Abstracts Database](#)
[EPO Abstracts Database](#)
[Derwent World Patents Index](#)
[IBM Technical Disclosure Bulletins](#)

Search:

L8

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History**
DATE: Friday, December 05, 2003 [Printable Copy](#) [Create Case](#)
Set Name Query
 side by side

Hit Count Set Name
 result set
DB=USPT; PLUR=YES; OP=OR

<u>L8</u>	L7 and inotophoresis	2	<u>L8</u>
<u>L7</u>	L6 and dimethyl sulfoxide	54630	<u>L7</u>
<u>L6</u>	l4 and inhibition	2132	<u>L6</u>
<u>L5</u>	MC148P	0	<u>L5</u>
<u>L4</u>	L3 and treatment	2657	<u>L4</u>
<u>L3</u>	L2 and l1	2712	<u>L3</u>
<u>L2</u>	atopic dermatitis	8494	<u>L2</u>
<u>L1</u>	molluscum contagiosum virus or MCV	56886	<u>L1</u>

END OF SEARCH HISTORY

WEST

Generate Collection

Print

Search Results - Record(s) 1 through 2 of 2 returned.☐ 1. Document ID: US RE38000 E

L8: Entry 1 of 2

File: USPT

Feb 25, 2003

US-PAT-NO: RE38000

DOCUMENT-IDENTIFIER: US RE38000 E

TITLE: Electrokinetic drug delivery apparatus

DATE-ISSUED: February 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Henley; Julian L.	Guilford	CT		

US-CL-CURRENT: 604/20

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-------

☐ 2. Document ID: US 6048545 A

L8: Entry 2 of 2

File: USPT

Apr 11, 2000

US-PAT-NO: 6048545

DOCUMENT-IDENTIFIER: US 6048545 A

TITLE: Liposomal delivery by iontophoresis

DATE-ISSUED: April 11, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Keller; Brian C.	Antioch	CA		
Fisher; Daniel L.	Pleasant Hill	CA		
Kiss; Stefan	Concord	CA		
Mezei; Michael	Halifax			CA

US-CL-CURRENT: 424/450; 424/1.21, 424/401, 424/9.321, 424/9.51, 604/20

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-------

Generate Collection

Print

Terms

Documents

L7 and iontophoresis

2

Display Format:

CIT

Change Format

Previous Page

Next Page

The logo consists of a black rectangular bar with the word "WEST" in white, bold, sans-serif capital letters centered within it.

Generate Collection

☐ Print

L8: Entry 1 of 2

File: USPT

Feb 25, 2003

DOCUMENT-IDENTIFIER: US RE38000 E

TITLE: Electrokinetic drug delivery apparatus

Other Reference Publication (11):

"The Quantity and Distribution of Radiolabeled Dexamethasone Delivered to Tissue by Inotophoresis," Glass et al.; International Journal of Dermatology, vol. 19, Nov. 1980, pp. 519-525.

Other Reference Publication (27):

"Early Application of Topical 15% Idoxuridine in Dimethyl Sulfoxide Shortens the Course of Herpes Simplex Labialis: A Multicenter Placebo-Controlled Trial," Spruance et al., The Journal of Infectious Diseases; 1990, 161; pp. 191-197.

WEST**End of Result Set**

Generate Collection

Print

L8: Entry 2 of 2

File: USPT

Apr 11, 2000

DOCUMENT-IDENTIFIER: US 6048545 A

TITLE: Liposomal delivery by iontophoresis

Detailed Description Text (31):

While not required to practice the method of the invention, permeability enhancers conventionally known in the art can also be present, usually about 1 to about 10% by w. Suitable permeability enhancers include fatty acid esters and fatty alcohol ethers of C.sub.1-4 alkanediols, alcohols such as ethanol, dimethyl sulfoxide, polyethylene glycol monolaurate and the like.

CLAIMS:

1. A method for administration of an substance selected from the group consisting of an uncharged dye and uncharged anesthetic to a subject comprising

applying directly to the skin or tissue of the subject a composition comprising said substance encapsulated within liposomes having either a positively or negatively charged surface by inotophoresis where the electric current is from about 1 to about 3 milliamperes and the duration is form about 1 to 15 minutes which causes dermal penetration.